Search results

Technologies 1

• Implantable Cancer Vaccine
  The Wyss Institute’s implantable, biodegradable cancer vaccine leverages immunotherapeutic methods and could one day help overcome melanoma, other cancers, infectious diseases, auto-immune diseases, as well as vaccinate against specific peptides, proteins, or antigens. The implant is a biodegradable polymer scaffold containing growth factors and components of each patient’s tumors. The technology was initially designed to...

Collaborations 1

• i3 Center: Biomaterials to Create T Cell Immunity
  Cancer immunologists and biological engineers are developing new biomaterials-based approaches to develop new anti-cancer immunotherapies for treatment-resistant cancers.

News 9

View all

• Press Release
  
  Planting the seed for DNA nanoconstructs that grow to the micron scale
  March 23, 2021
• Research Spotlights
  
  Harvard “Immuno-engineering to Improve Immunotherapy” (i3) Center at the Wyss Institute awards first grant to Dana-Farber cancer immunologist Eric Smith
  January 21, 2021
• Research Spotlights
  
  i3 Center: Biomaterials to Create T Cell Immunity
  July 1, 2020

Multimedia 2

• 

  Audio/Podcast
  Disruptive: Cancer Vaccine & Hydrogel Drug Delivery
  In this episode of Disruptive, Wyss Founding Core Faculty Member Dave Mooney discusses programmable nanomaterials approaches to fighting disease. Mooney explains how a cancer vaccine, developed by his team and currently in a clinical trial at the Dana-Farber Cancer Institute, can train one’s own immune system to target specific cancer cells. He also describes the...

• 

  Video/Animation
  Introduction to Implantable Cancer Vaccine
  What if we could prevent and treat cancer with a simple vaccine? Credit: Wyss Institute at Harvard University